Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Nearly two years after Shire, the speciality medicines group, bought Transkaryotic Therapies, a US ...
Shire Pharmaceuticals said yesterday that it had signed a definitive agreement to acquire Transkaryotic Therapies, in a $1.6 billion dollar, all-cash deal. Shire Pharmaceuticals said yesterday that it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results